- Home
- KC vs AKRO Comparison
KC vs AKRO Comparison
Compare KC & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KC
- AKRO
- Stock Information
- Founded
- KC 2012
- AKRO 2017
- Country
- KC China
- AKRO United States
- Employees
- KC N/A
- AKRO N/A
- Industry
- KC Computer Software: Prepackaged Software
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- KC Technology
- AKRO Health Care
- Exchange
- KC Nasdaq
- AKRO Nasdaq
- Market Cap
- KC 2.5B
- AKRO 2.0B
- IPO Year
- KC 2020
- AKRO 2019
- Fundamental
- Price
- KC $9.55
- AKRO $25.60
- Analyst Decision
- KC Strong Buy
- AKRO Strong Buy
- Analyst Count
- KC 7
- AKRO 8
- Target Price
- KC $5.69
- AKRO $46.83
- AVG Volume (30 Days)
- KC 2.9M
- AKRO 842.7K
- Earning Date
- KC 11-19-2024
- AKRO 02-27-2025
- Dividend Yield
- KC N/A
- AKRO N/A
- EPS Growth
- KC N/A
- AKRO N/A
- EPS
- KC N/A
- AKRO N/A
- Revenue
- KC $1,037,206,927.00
- AKRO N/A
- Revenue This Year
- KC $11.27
- AKRO N/A
- Revenue Next Year
- KC $11.96
- AKRO N/A
- P/E Ratio
- KC N/A
- AKRO N/A
- Revenue Growth
- KC N/A
- AKRO N/A
- 52 Week Low
- KC $2.02
- AKRO $15.32
- 52 Week High
- KC $12.84
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- KC 50.73
- AKRO 44.22
- Support Level
- KC $9.12
- AKRO $21.34
- Resistance Level
- KC $10.28
- AKRO $28.94
- Average True Range (ATR)
- KC 0.56
- AKRO 1.35
- MACD
- KC -0.27
- AKRO -0.09
- Stochastic Oscillator
- KC 16.23
- AKRO 56.05
About KC Kingsoft Cloud Holdings Limited
Kingsoft Cloud Holdings Ltd is an independent cloud service provider in China. It provides integrated cloud-based services including cloud computing, storage, and delivery. Its products and services are Safety, database, AI, hybrid cloud and others. Its solutions are medical, government affairs, finance, media, Educate, game, Transportation and Logistics, Audio, and video.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.